Edgar Filing: ENDOLOGIX INC /DE/ - Form 4

ENDOLOGIZ Form 4 May 27, 2014	l .						OMB A	PPROVAL	
Check this box if no longer subject to Section 16. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-02 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: January 3							3235-0287 January 31, 2005 average irs per		
1. Name and Ac Machek Jame	ddress of Reporting Person <u>*</u> es Edward	2. Issuer Name and Ticker or Trading Symbol ENDOLOGIX INC /DE/ [ELGX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 11 STUDEB	(First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/22/2014				Director 10% Owner X Officer (give title Other (specify below) below) VP-Research & Development			
Filed(Month/Day/Year) Aj					Applicable Line) _X_ Form filed by	X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State) (Zip)	Table I - Non-D	erivative So	ecurit	ties Ac	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	any	cion Date, if Transactio Code n/Day/Year) (Instr. 8)		(A) or of (D 4 and (A) or) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/22/2014	A	Amount 6,074 (1)	(D) A	Price \$ 0	17,263	D		
Common Stock	05/22/2014	А	6,074 (2)	А	\$0	23,337	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: ENDOLOGIX INC /DE/ - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities8(Instr. 3 and 4)9	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase	\$ 13.17	05/22/2014		А	15,267	(3)	05/22/2024	Common Stock	15,267

Reporting Owners

Reporting Owner Name / Address	Relationships							
1	Director	10% Owner	Officer	Other				
Machek James Edward 11 STUDEBAKER IRVINE, CA 92618			VP-Research & Development					
Signatures								
James E. Machek by Timothy N. Brady, Attorney-in-Fact for Reporting Person.								

<u>**</u>Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Time based restricted stock unit award.
- (2) Performance restricted stock unit award based on clinical and revenue milestones.
- (3) 25% of options vest after one year of service. The remaining 75% of options vest ratably over the following thirty-six months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Date